rituximab/yttrium Y 90 ibritumomab tiuxetan

Known as: IDEC-Y2B8/MOAB IDEC-C2B8 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2010
02419972010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
The chimeric anti-CD20 antibody rituximab (Rituxan, IDEC-C2B8) is widely used in the clinical treatment of patients with non… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Rituximab (Rituxan, IDEC-C2B8) has been shown to sensitize non-Hodgkin's lymphoma (NHL) cell lines to chemotherapeutic drug… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
The anti-CD20 monoclonal antibody rituximab (Rituxan, IDEC-C2B8) has shown promising results in the clinical treatment of a… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2001
2001
Mantle cell lymphoma (MCL) has a poor prognosis without cure; the median overall survival ranges only from 3 to 4 years… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to normal organs… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Eleven patients with relapsed fludarabine-resistant B-cell chronic lymphocytic leukemia (CLL) or leukemic variants of low-grade B… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1999
1999
This study focused on the efficacy of IDEC-C2B8 (chimeric anti-CD20) immunotherapy relative to specific subtypes of low-grade… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
BACKGROUND Monoclonal antibodies are being utilized for treatment of patients with low-grade non-Hodgkin's lymphoma as well as… (More)
Is this relevant?
1998
1998
BACKGROUND In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?